Bixiye
P15-24 New Medical, Medical Drug and Behavioral Health Policy Management Updates, Effective May 6, 2024
Taariikhda uu dhaqangalayo Barnaamijka: Mar 01, 2024
Natiijooyinka Raadinta
Soo bandhiga 861 - 870 ee natiijooyinka 4226
Bixiye
P14-24 Medicare Part B Step Therapy Program Expansion to Include Rystiggo, and Vyvgart Hytrulo
Taariikhda uu dhaqangalayo Barnaamijka: Mar 01, 2024
Bixiye
P54-24 Changes to the Medication Therapy Management (MTM) Program, Effective January 1, 2025
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Bixiye
P57-24 MagellanRx Management, a Prime Therapeutics Company (UM) Program: Medical Drug Updates
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Bixiye
2024 September Bulletins
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Bixiye
P45R1-24 Updated Reimbursement Policies, Effective September 3, 2024
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Bixiye
P55-24 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 03, 2024
Bixiye
QP68-24 MHCP Pharmacy Benefit Exclusion for Kisunla™, PiaSky®, and Tecelra®
Taariikhda barnaamijka Dhaqangalayso Agosto 28, 2024
Bixiye
QP67-24 Commercial Pharmacy Benefit Exclusion for edaravone, Kisunla™, PiaSky®, and Tecelra®
Taariikhda barnaamijka Dhaqangalayso Agosto 28, 2024
Bixiye
QP65-24 PCA Agency Requirements
Taariikhda barnaamijka Dhaqangalayso Agosto 28, 2024